Saga Diagnostics expanded the use of its ultrasensitive blood test to include detection of tiny amounts of colorectal cancer ...

While the 2026 J.P. Morgan Healthcare Conference has thus far failed to yield any major M&A deals for the industry, Medtronic believes the time is ripe for buyouts. | While the 2026 J.P. Morgan ...

In his inaugural J.P. Morgan Healthcare Conference speech, newly minted Dexcom CEO Jake Leach looked to ease concerns over ...

After a year of significant disruption at Novo Nordisk, the company's R&D chief has told Fierce Biotech that the deal-hungry ...

It’s been a subdued—albeit sunny—start to healthcare’s biggest conference in San Francisco. | It’s been a subdued—albeit ...

Lyra Therapeutics is abandoning work on its rhinosinusitis treatment and laying off its remaining employees.

Gary Gibbons, M.D., is retiring as National Heart, Lung and Blood Institute (NHLBI) director, adding to the e | Gary Gibbons, ...

The life sciences world is once again converging in San Francisco as the J.P. Morgan Healthcare Conference kicks off for 2026 ...

Thermo Fisher Scientific is starting 2026's J.P. Morgan Healthcare Conference with a bang, announcing two new deals with an ...

Eli Lilly and Nvidia, two primary drivers of the recent stock market rally, are deepening their alliance to connect silicon ...

Teva has penned a second pact with Royalty Pharma, this time securing up to $500 million to support the clinical development ...

AbbVie has made no secret of the fact that it’s taken an interest in the hotly contested PD-1xVEGF bispecific space. | AbbVie has made no secret of the fact that it's taken an interest in the hotly ...